End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,360 KRW | -3.74% | -1.51% | -8.58% |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Bio
85.5
%
| 440 | 57.8 % | 2,723 | 85.5 % | +519.02% |
System
13.4
%
| 280 | 36.8 % | 426 | 13.4 % | +52.27% |
Others
1.1
%
| 41 | 5.4 % | 35 | 1.1 % | -13.47% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
72.8
%
| - | - | 2,318 | 72.8 % | - |
South Korea
26.2
%
| 562 | 73.9 % | 833 | 26.2 % | +48.27% |
Asia
1.0
%
| - | - | 33 | 1.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Byung-Hee Jeon
CEO | Chief Executive Officer | 65 | - |
Myung-Chul Lee
AUD | Comptroller/Controller/Auditor | 62 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Byung-Hee Jeon
CEO | Chief Executive Officer | 65 | - |
Jong-Gil Lee
BRD | Director/Board Member | 55 | - |
Myung-Shin Kim
BRD | Director/Board Member | 56 | - |
Jae-Il Shin
BRD | Director/Board Member | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 22,423,102 | 13,461,655 ( 60.03 %) | 60,000 ( 0.2676 %) | 60.03 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CYTOGEN, INC. 0.27% | 60,000 | 0.27% | 615,933 $ |
Company contact information
CytoGen, Inc.
8/F, Munjeong SK beuyiwon metro city 128 Beobwon-ro
05854, Seoul
+
http://www.cytogenlab.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-8.58% | 209M | |
-20.55% | 10.82B | |
+47.97% | 3.25B | |
-32.75% | 2.11B | |
-14.15% | 2.08B | |
-26.06% | 1.48B | |
+19.85% | 1.02B | |
-2.62% | 733M | |
-31.67% | 391M | |
-43.88% | 383M |
- Stock Market
- Equities
- A217330 Stock
- Company Cytogen, Inc.